Brief: Graphite Bio Enrolls First Patient In Phase 1/2 Clinical Trial Of Gph101 For Sickle Cell Disease

LENZ Therapeutics

17/11/2021 13:19

Nov 17 (Reuters) - Graphite Bio Inc  GRPH.O :
    * GRAPHITE BIO ENROLLS FIRST PATIENT IN PHASE 1/2 CLINICAL
TRIAL
OF GPH101 FOR SICKLE CELL DISEASE

Source text for Eikon:  ID:nBw3w2t8qa 
Further company coverage:  GRPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))